Getein Biotech(SH:603387) Zheng Quan Zhi Xing·2025-05-15 09:16Core Points - The company Getein Biotech, Inc. is preparing for its 2024 Annual General Meeting (AGM) scheduled for May 22, 2025, in Nanjing, China, where various proposals will be discussed and voted on [1][2][3]. Proposal Summaries - Proposal 1: Approval of the 2024 Annual Report and its summary, which reflects the company's operational performance for the year [5][6]. - Proposal 2: Approval of the 2024 Board of Directors' Work Report, detailing the board's activities and responsibilities throughout the year [6][7]. - Proposal 3: Approval of the 2024 Supervisory Board Work Report, which outlines the supervisory activities and compliance with regulations [17][18]. - Proposal 4: Approval of the 2024 Financial Settlement Report, including audited financial statements and key financial metrics [21][22]. - Proposal 5: Discussion of the profit distribution plan for 2024, which will be based on the company's financial performance [1][5]. - Proposal 6: Approval of the remuneration for directors and senior management, ensuring alignment with company performance [1][5]. - Proposal 7: Approval of the remuneration for supervisors, maintaining transparency and accountability [1][5]. - Proposal 8: Authorization for the use of idle funds for investment and financial management, aimed at optimizing asset utilization [1][5]. - Proposal 9: Approval for the company and its subsidiaries to apply for comprehensive credit lines from banks, facilitating financial flexibility [1][5]. - Proposal 10: Reappointment of the accounting firm for the annual audit, ensuring compliance and accuracy in financial reporting [1][5]. - Proposal 11: Expansion of the company's business scope and amendments to the Articles of Association, reflecting strategic growth initiatives [1][5]. - Proposal 12: Authorization for the Board to formulate and implement a mid-term dividend plan, enhancing shareholder returns [1][5]. Meeting Logistics - The AGM will combine in-person attendance and online voting, with specific time slots for participation [3][4]. - The meeting will be presided over by the Board of Directors, ensuring structured proceedings and adherence to legal requirements [3][4]. Financial Performance Overview - The company reported a revenue of approximately CNY 1.16 billion for 2024, a decrease of 14.93% from the previous year [21][22]. - Net profit attributable to shareholders was approximately CNY 223.64 million, down 20.06% year-on-year [21][22]. - The company’s total assets stood at approximately CNY 3.71 billion, reflecting a slight decrease of 1.70% compared to the previous year [21][22]. - The net asset value attributable to shareholders increased by 2.33% to approximately CNY 2.62 billion [21][22]. Governance and Compliance - The Board of Directors and Supervisory Board have conducted their duties in accordance with relevant laws and regulations, ensuring proper governance and oversight [17][18]. - The company has maintained a focus on improving internal controls and compliance, with regular audits and evaluations of financial practices [19][20].